v3.26.1
Segment Information (Tables)
 12 Months Ended
Dec. 31, 2025
Segment Reporting [Abstract]  
Schedule of Segment Reporting Information, by Segment
The following is a summary of our segment and consolidated net loss, including significant segment expenses:
Year Ended
December 31,
20252024
(in thousands)
Collaboration revenue$— $1,885 
Less:
Clinical development19,187 16,361 
Research and discovery12,660 14,389 
General and administrative support12,428 14,330 
Manufacturing8,523 19,759 
Other segment expenses(a)
7,879 10,640 
Interest income3,108 6,673 
Interest expense(5,274)(4,656)
Loss on extinguishment of debt— (553)
Other income, net2,021 1,615 
Segment and consolidated net loss$(60,822)$(70,515)
(a) Other segment expenses includes non-cash expenses for stock-based compensation and depreciation expenses.